Abstract
Metastatic extramammary breast tumours are uncommon and differential diagnosis with primary breast carcinoma may prove to be difficult. We report a case of a metastasis of a renal cell cancer in the breast in a woman with a history of primary breast cancer. On follow-up of her breast carcinoma, a lump was detected via mammography and ultrasound. Core needle biopsy revealed a metastatic extramammary lesion originating from an asymptomatic renal cell carcinoma. We conclude that the diagnosis of metastasis to the breast from extramammary tumours is important to avoid unnecessary surgery and insure proper treatment of the primary disease.
Highlights
Case reportA 83-year-old caucasian woman developed a ductal breast carcinoma in the right breast (pT2 N0 M0) in
In august 2008, the mass in the right breast is growing without progression of the other metastatic lesions and primary tumour
Primary tumours more frequently have microcalcifications or spiculations while metastatic extramammary breast lesions usually are wellcircumscribed without calcifications or an intraductal component
Summary
A 83-year-old caucasian woman developed a ductal breast carcinoma in the right breast (pT2 N0 M0) in. She underwent a tumorectomy and a right axillary lymph node dissection followed by radiotherapy. She had been treated with tamoxifen during five years. — Mammography of the right breast (mediolateral oblique view) in 2005 (A) and 2007 (B) shows a well-marginated new opacity (arrow) in the axillary tail with a diameter of 6 mm (B). In July 2007 CNB (Fig. 4) showed ginated opacity in the axillary tail of The left side only showed some morphologically a metastasis of a the right breast with a diameter of lymph nodes. — Mammography of the left breast (mediolateral oblique view) in 2005 (A) and 2007 (B) demonstrates the apparition of a sharply marginated opacity (arrow) in the axillary tail with a diameter of 7 mm. In august 2008, the mass in the right breast is growing without progression of the other metastatic lesions and primary tumour
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have